Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Autosomal dominant intermediate Charcot-Marie-Tooth disease type D is a rare hereditary motor and sensory neuropathy characterized by intermediate motor median nerve conduction velocities (usually between 25 and 45 m/s) and signs of both axonal degeneration and demyelination without onion bulbs in nerve biopsies. It presents with usual Charcot-Marie-Tooth disease clinical features of variable severity (progressive muscle weakness and atrophy of the distal extremities, distal sensory loss, reduced or absent deep tendon reflexes, and feet deformities). Other findings in some of the families include debilitating neuropathic pain and mild postural/kinetic upper limb tremor.
Features include: Hyporeflexia, Axonal degeneration/regeneration, Distal amyotrophy, and Upper limb muscle weakness and 4 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 2 | Upper limb muscle weakness, Distal muscle weakness |
Brain and nerves | 1 | Hyporeflexia |
Arms and legs | 1 | Upper limb muscle weakness |
Age of onset: adulthood.
MPZ encodes myelin protein zero (248 aa). Is an adhesion molecule necessary for normal myelination in the peripheral nervous system. It mediates adhesion between adjacent myelin wraps and ultimately drives myelin compaction Highest expression in Nerve Tibial (5,301 TPM) and Colon Sigmoid (33.9 TPM).
Charcot-Marie-Tooth disease dominant intermediate D is associated with mutations in the MPZ gene on chromosome 1.
The MPZ protein participates in MPZ gene:EGR2:SOX10:SMARCA4, MPZ gene expression, and EGR2, SOX10 and SMARCA4 bind the MPZ gene pathways.
MPZ is classified as a druggable target (Druggable Genome category) with score 0.0.
Genetic testing for MPZ is available. Testing is considered confirmatory for diagnosis.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Charcot-Marie-Tooth disease dominant intermediate D.
5 publications have been identified in PubMed for Charcot-Marie-Tooth disease dominant intermediate D. Research spans Gene Therapy / Novel Therapeutics (40%), Review / Meta-Analysis (20%), and Basic Science / Preclinical (20%).
Georgiou E (2026). [PMID: 42120546](https://pubmed.ncbi.nlm.nih.gov/42120546/). *Gene Ther*. [Gene Therapy / Novel Therapeutics]
Christou M (2025). [PMID: 40055046](https://pubmed.ncbi.nlm.nih.gov/40055046/). *Neurotherapeutics*. [Gene Therapy / Novel Therapeutics]
Cakar A (2025). [PMID: 39776111](https://pubmed.ncbi.nlm.nih.gov/39776111/). *Eur J Neurol*. [Epidemiology / Natural History]
Zhu J (2025). [PMID: 39986019](https://pubmed.ncbi.nlm.nih.gov/39986019/). *Stem Cell Res*. [Basic Science / Preclinical]
McCulloch MK (2024). [PMID: 39273178](https://pubmed.ncbi.nlm.nih.gov/39273178/). *Int J Mol Sci*. [Review / Meta-Analysis]
Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 11:36 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Charcot-Marie-Tooth disease dominant intermediate D